The 5-star Raffles Hotel in Boston was a fitting location for the launch of Singapore’s fifth international hub in the U.S., ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

MelliCell CEO Ben Pope, Ph.D., echoed the need for increased access to funds. The Greater Boston-based biotech company has a ...

Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion ...

The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from ...

Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June. Plump joined the Japanese drugmaker in 2015, arriving from Sanofi to initially serve as ...

Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladd | Tyra Biosciences has reported initial phase 2 ...

Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up ...

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the ...

Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has flunked another phase 2 trial, wiping out the biotech’s ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Clinical research company nPhase has launched an end-to-end clinical data management platform designed to help trial sponsors ...